Editor's Note: the "Trending USA Stocks" column tracks the day's top bullish stocks in the USA market, aiding investors in promptly identifying opportunities for potential gains.

27/07/2026 Eastern Time in the USA: The Dow Jones Industrial Average rose by 0.51%, closing at 52210.08 points; the Nasdaq Composite dropped by 0.18%, closing at 24932.08 points; the S&P 500 Index rose by 0.02%, closing at 7413.18 points. Sahm has compiled the Top 10 Daily Stock Price Gainers in the USA market.

Entera Bio Ltd.: Overnight gain 91.2%, Surges Amid Oversubscribed Private Placement Led by Top Healthcare Institutions

Entera Bio Ltd.: Clinical-Stage Innovator Pioneering Oral Peptide and Protein Replacement Therapies** Entera Bio Ltd. was incorporated in September 2009 and commenced formal business operations in June 2010. The Company is a clinical-stage biopharmaceutical enterprise focused on the development of first-in-class oral tablet formulations of peptide and protein replacement therapies. Entera Bio targets chronic disease indications characterized by significant unmet medical needs, with a strategic mission to transform existing treatment paradigms through the advancement of orally administered protein therapeutics.

Entera Bio Ltd. (ENTX) Surges 91.2% Following Oversubscribed $275M Private Placement** Shares of Entera Bio Ltd. (ENTX) soared 91.2% in a single session after the company announced the successful completion of an approximately $275 million oversubscribed private placement financing. The round was led by BVF Partners, with participation from premier healthcare investors including Longitude Capital, Vivo Capital, RA Capital Management, and Perceptive Advisors, whose collective institutional endorsement significantly bolstered market confidence. Proceeds will be deployed to advance EB613 — the world's first oral PTH(1-34) peptide tablet — through Phase III pivotal clinical trials and support an NDA submission to the FDA, while also funding Phase I development of EB612 for hypoparathyroidism. The financing extends Entera Bio Ltd.'s (ENTX) cash runway through 2030, effectively eliminating near-term refinancing concerns. Additionally, BVF secured the right to nominate two board seats, further strengthening corporate governance.

LiveWire: Overnight gain 66.4%, Surges Amid Strong Revenue Beat, Narrowing Losses, and New Model Launch

LiveWire Group, Inc. Establishes Foothold in Premium Electric Motorcycle Segment** LiveWire Group, Inc. was incorporated in the State of Delaware on December 7, 2021, with a strategic mandate to drive transformative change across the all-electric motorcycle industry. Parent company Harley-Davidson (H-D) first entered the electric vehicle space in 2014 with the launch of its inaugural electric models, subsequently conducting extensive global testing programs. Buoyed by favorable market reception and sustained growth in global electric vehicle demand, H-D elected to spin off LiveWire as a dedicated electric vehicle division in 2021, underscoring its commitment to accelerating the electrification of two-wheel mobility. The division's flagship product, the LiveWire ONE, made its official market debut in July of the same year and has since entered full-scale commercial production. The successful launch and subsequent rollout of the LiveWire ONE have positioned the company to progressively consolidate its standing as a leading force in the premium electric motorcycle segment, as the broader industry continues its transition toward sustainable powertrain solutions.

LiveWire(LVWR) Surges 66.4% Following Stronger-Than-Expected Q2 FY2026 Results** LiveWire(LVWR) shares posted a dramatic single-session gain of 66.4%, driven by a confluence of fundamental catalysts and technical dynamics. The company reported Q2 FY2026 consolidated revenue of $9.1 million, representing a robust 55% year-over-year increase that materially exceeded market consensus, serving as the primary catalyst. Net loss narrowed 3% to $18.2 million, while adjusted EBITDA loss improved 4% to $15.1 million, reflecting continued operational efficiency gains. On the strategic front, LiveWire(LVWR) commenced mass production of the new S4 Honcho platform, with two competitively priced lightweight electric motorcycles poised to penetrate the mass market. The completed acquisition of Dust Motorcycles further diversifies its product portfolio. Full-year guidance was reaffirmed, underscoring management confidence. Additionally, the stock's 45% year-to-date decline ahead of results amplified the upside move, triggering concentrated short-covering and sentiment-driven buying pressure.

FORTE BIOSCIENCES INC: Overnight gain 39.6%, Surges Amid Argenx Acquisition Bid and Barclays Overweight Rating

FORTE BIOSCIENCES INC Advances Live Biotherapeutic Candidate FB-401 for Inflammatory Skin Conditions Amid Strong Market Demand** Forte Biosciences, Inc. (the "Company") is a clinical-stage dermatology company dedicated to the development of FB-401, a proprietary live biotherapeutic product candidate targeting inflammatory skin diseases. The Company has successfully completed Phase 1/2a clinical trials evaluating FB-401 in adult patients as well as pediatric patients aged three years and older diagnosed with atopic dermatitis. The atopic dermatitis therapeutics market continues to exhibit robust unmet medical need for safe and efficacious treatment options, with particular emphasis on the underserved pediatric patient population. Against this backdrop, Forte Biosciences is strategically positioned to address a significant gap in the current treatment landscape. Looking ahead, the Company has outlined plans to advance FB-401 into Phase 2 clinical development in the mid-2020s, representing a key milestone in its clinical pipeline progression. Management remains committed to leveraging the emerging field of live biotherapeutics to deliver differentiated therapeutic solutions for patients suffering from chronic inflammatory dermatological conditions.

FORTE BIOSCIENCES INC (FBRX) Surges Pre-Market Following Acquisition Announcement** Shares of FORTE BIOSCIENCES INC (FBRX) surged 39.6% in pre-market trading to $76.10, ranking among the top gainers in U.S. equities, after argenx SE (NASDAQ: ARGX) announced a definitive agreement to acquire Forte Biosciences at $77.00 per share in cash, implying a total transaction value of approximately $2.2 billion. The deal has propelled FBRX's year-to-date gains to 180.5%, with market capitalization reaching approximately $1.16 billion. Adding further momentum, Barclays analyst Etzer Darout initiated coverage of FORTE BIOSCIENCES INC (FBRX) with an **Overweight** rating and a price target of $74.00. The convergence of the premium acquisition offer and a bullish analyst initiation has significantly bolstered investor confidence, reinforcing the stock's strong upward trajectory heading into the session.

The Top 10 Daily Gainers in the USA market are listed as follows: